Table 1.

Summary of study designs for the studies included in this meta-analysis

Study	Design	Treatment arms	Number of patients	Treatment duration
Donohue [5]	Phase III, randomized, double-blind (indacaterol and placebo) or open-label (tiotropium), placebo-controlled, parallel-group, multicentre	Indacaterol 150 μg od	1683 randomized;	26 weeks
		Indacaterol 300 μg od	1665 evaluable for efficacy
		Tiotropium 18 μg od
		Placebo
Dahl [6]	Phase III, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicentre	Indacaterol 300 μg od	1732 randomized;	52 weeks
		Indacaterol 600 μg od	1600 evaluable for efficacy
		Formoterol 12 μg bid
		Placebo
Kornmann [7]	Phase III, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicentre	Indacaterol 150 μg od	1002 randomized;	26 weeks
		Salmeterol 50 μg bid	998 evaluable for efficacy
		Placebo
Gotfried-1 [8]	Phase III, randomized, double-blind, placebo-controlled, parallel-group, in the United States	Indacaterol 75 μg od	323 randomized;	12 weeks
		Placebo	323 evaluable for efficacy
Gotfried-2 [8]	Phase III, randomized, double-blind, placebo-controlled, parallel-group, in the United States	Indacaterol 75 μg od	318 randomized;	12 weeks
		Placebo	317 evaluable for efficacy
Kinoshita [9]	Phase III, randomized, double-blind, placebo-controlled, parallel-group, in six Asian areas	Indacaterol 150 μg od	347 randomized;	12 weeks
		Indacaterol 300 μg od	347 evaluable for efficacy
		Placebo

od = once-daily; bid = twice-daily.